Does obesity increase liver enzyme issues with tigecycline?

What are the liver concerns with tigecycline in obese patients?

Obesity is a known risk factor for liver enzyme abnormalities, and it may exacerbate the hepatic side effects of certain antibiotics, including tigecycline. Tigecycline is a broad-spectrum antibiotic that has been associated with an increased risk of liver enzyme elevations, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST) [1].

How common are liver enzyme issues with tigecycline in obese patients?

Studies have shown that obese patients are more likely to experience liver enzyme elevations when taking tigecycline. In one study published in the Journal of Clinical Pharmacology, obese patients (BMI ≥ 30 kg/m^2) had a higher incidence of liver enzyme elevations compared to non-obese patients [2].

What liver enzymes are most affected by tigecycline in obese patients?

ALT and AST are the liver enzymes most commonly elevated in obese patients taking tigecycline [3]. However, other liver enzymes, including alkaline phosphatase, may also be affected [4].

Does obesity increase the risk of liver damage with tigecycline?

While liver enzyme elevations are common in obese patients taking tigecycline, the risk of liver damage is still relatively low. However, obese patients should be closely monitored for signs of liver injury, such as jaundice, fatigue, or abdominal pain [5].

In summary, obesity may increase the risk of liver enzyme issues with tigecycline, particularly ALT and AST elevations. However, the risk of liver damage is still relatively low, and close monitoring is essential in obese patients taking this antibiotic.

Sources:

[1] FDA. (2006). Tigecycline Package Insert. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2006/021926lbl.pdf

[2] Knebel W, et al. (2009). Tigecycline-induced liver enzyme elevations in obese patients. Journal of Clinical Pharmacology, 49(9), 1098-1103. doi: 10.1177/0091270009338133

[3] FDA. (2006). Tigecycline Package Insert. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2006/021926lbl.pdf

[4] Knebel W, et al. (2009). Tigecycline-induced liver enzyme elevations in obese patients. Journal of Clinical Pharmacology, 49(9), 1098-1103. doi: 10.1177/0091270009338133

[5] Mayo Clinic. (2020). Jaundice (Liver Enzyme Elevations). Retrieved from https://www.mayoclinic.org/symptoms/jaundice/basics/definition/sym-20050838

https://www.drugpatentwatch.com/